公开(公告)号：US20200009195A1

公开(公告)日：2020-01-09

申请号：US16490777

申请日：2018-02-22

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yui Ueno ,  Hidenori Nonaka

IPC: A61K35/28 ,  A61P1/16

Abstract: The purpose of the present invention is to provide a novel therapeutic agent for liver disease. The present invention is a mesenchymal stem cell characterized by high expression of the Tissue Factor Pathway Inhibitor (TFPI). It is preferable that the mesenchymal stem cell is allogeneic and is derived from a fatty tissue. Moreover, the present invention includes a therapeutic agent for liver disease containing the mesenchymal stem cell.

公开(公告)号：US11253550B2

公开(公告)日：2022-02-22

申请号：US16490777

申请日：2018-02-22

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yui Ueno ,  Hidenori Nonaka

IPC: A61K35/28 ,  A61P1/16

Abstract: The purpose of the present invention is to provide a novel therapeutic agent for liver disease. The present invention is a mesenchymal stem cell characterized by high expression of the Tissue Factor Pathway Inhibitor (TFPI). It is preferable that the mesenchymal stem cell is allogeneic and is derived from a fatty tissue. Moreover, the present invention includes a therapeutic agent for liver disease containing the mesenchymal stem cell.

公开(公告)号：US20200016211A1

公开(公告)日：2020-01-16

申请号：US16490790

申请日：2018-02-22

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yui Ueno ,  Hidenori Nonaka

IPC: A61K35/28 ,  A61K38/17

Abstract: The purpose of the present invention is to provide a mesenchymal stem cell that is highly safe when used as a medicine. The present invention is a mesenchymal stem cell characterized in that the Tissue Factor (TF) is expressed at low levels. Furthermore, the present invention includes a mesenchymal stem cell characterized in that at least one integrin gene selected from the group consisting of ITGA11, ITGA1, ITGB5, ITGBL1, ITGB1 and ITGAV is expressed at low levels. Furthermore, the present invention includes a mesenchymal stem cell characterized in that at least one integrin gene selected from the group consisting of ITGA4, ITGA9, ITGA7, and ITGA10 is expressed at high levels. It is preferable that the mesenchymal stem cell is allogeneic and is derived from a fatty tissue. The present invention also includes a pharmaceutical composition containing the mesenchymal stem cell.